Dashboard
Manage Tickers

IFRXInflaRx N.V.

Nasdaq inflarx.de


$ 1.49 $ -0.15 (-9.2 %)    

Thursday, 23-May-2024 15:56:30 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 454.82 $ -2.05 (-0.45 %)
DIA $ 398.57 $ -6.00 (-1.51 %)
SPY $ 530.36 $ -3.87 (-0.73 %)
TLT $ 91.26 $ -0.59 (-0.64 %)
GLD $ 225.37 $ -4.39 (-1.99 %)
$ 1.48
$ 1.61
$ 0.00 x 0
$ 0.00 x 0
$ 1.46 - $ 1.62
$ 1.14 - $ 4.70
263,020
na
87.15M
$ 0.65
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-inflarx-maintains-8-price-target
HC Wainwright & Co. Reiterates Buy on Infl...
05/09/2024 10:52:12

HC Wainwright & Co. analyst Edward White reiterates InflaRx (NASDAQ:IFRX) with a Buy and maintains $8 price target.

inflarx-q1-2024-gaap-eps-018-beats-022-estimate-sales-39138k-miss-1268m-estimate
InflaRx Q1 2024 GAAP EPS $(0.18) Beats $(0...
05/08/2024 11:34:01

InflaRx (NASDAQ:IFRX) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.22) by 15...

hc-wainwright--co-reiterates-buy-on-inflarx-maintains-8-price-target
HC Wainwright & Co. Reiterates Buy on Infl...
03/22/2024 12:22:47

HC Wainwright & Co. analyst Edward White reiterates InflaRx (NASDAQ:IFRX) with a Buy and maintains $8 price target.

inflarxs-inf904-will-initially-target-chronic-spontaneous-urticaria-and-hidradenitis-suppurativa-with-initiation-of-a-phase-2a-pk-dose-ranging-study-expected-by-the-end-of-2024-with-data-availability-anticipated-in-2025
InflaRx's INF904 Will Initially Target Chr...
03/21/2024 11:15:06

inflarx-will-focus-development-activities-and-resources-initially-on-selected-indications-in-immuno-dermatology-with-registrational-phase-vilobelimab-and-inf904
InflaRx Will Focus Development Activities ...
03/21/2024 11:14:33

inflarx-fy-eps-078-down-from-067-yoy-sales-6309k
InflaRx FY EPS €(0.78) Down From €(0.67) Y...
03/21/2024 11:13:03

earnings-scheduled-for-march-21-2024
Earnings Scheduled For March 21, 2024
03/21/2024 10:15:14

Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per s...

earnings-preview-inflarx
Earnings Preview: InflaRx
03/20/2024 17:01:53

why-tellurian-shares-are-trading-higher-by-over-16-here-are-20-stocks-moving-premarket
Why Tellurian Shares Are Trading Higher By...
01/26/2024 12:58:39

Shares of Tellurian Inc. (NASDAQ: TELL) shares rose sharply in pre-market trading following a report suggesting the company hi...

hc-wainwright--co-maintains-buy-on-inflarx-lowers-price-target-to-8
HC Wainwright & Co. Maintains Buy on Infla...
01/25/2024 16:24:00

HC Wainwright & Co. analyst Edward White maintains InflaRx (NASDAQ:IFRX) with a Buy and lowers the price target from $9 ...

inflarx-reports-topline-results-from-multiple-ascending-dose-part-of-its-randomized-double-blind-placebo-controlled-phase-i-trial-for-inf904-to-advance-inf904-into-phase-ii-clinical-development
InflaRx Reports Topline Results From Multi...
01/04/2024 12:03:40

INF904 was well tolerated and there were no adverse safety events of concern after repeated dosing in participants over the ent...

inflarx-announces-that-the-first-patient-has-been-dosed-in-its-phase-3-study-investigating-the-efficacy-and-safety-of-vilobelimab-in-pyoderma-gangrenosum
InflaRx Announces That The First Patient H...
11/06/2023 12:36:24

why-digitalocean-shares-are-trading-higher-by-around-20-here-are-20-stocks-moving-premarket
Why DigitalOcean Shares Are Trading Higher...
11/03/2023 12:41:43

Gainers Altamira Therapeutics Ltd (NASDAQ: CYTO) shares surged 54.1% to $0.25 in pre-market trading after gaining 5% on Thursday.

raymond-james-maintains-strong-buy-on-inflarx-lowers-price-target-to-19
Raymond James Maintains Strong Buy on Infl...
11/02/2023 16:24:57

Raymond James analyst Steven Seedhouse maintains InflaRx (NASDAQ:IFRX) with a Strong Buy and lowers the price target from $2...

hc-wainwright--co-reiterates-buy-on-inflarx-maintains-9-price-target
HC Wainwright & Co. Reiterates Buy on Infl...
09/12/2023 10:10:59

HC Wainwright & Co. analyst Edward White reiterates InflaRx (NASDAQ:IFRX) with a Buy and maintains $9 price target.

inflarx-announces-topline-results-from-the-single-ascending-dose-sad-phase-i-study-with-c5ar-inhibitor-inf904
InflaRx Announces Topline Results from the...
09/11/2023 11:03:20

InflaRx N.V. (NASDAQ:IFRX), a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, ...

hc-wainwright--co-reiterates-buy-on-inflarx-maintains-9-price-target
HC Wainwright & Co. Reiterates Buy on Infl...
08/31/2023 08:15:20

HC Wainwright & Co. analyst Edward White reiterates InflaRx (NASDAQ:IFRX) with a Buy and maintains $9 price target.

inflarxs-marketing-authorization-application-maa-for-vilobelimab-for-treatment-of-critically-ill-covid-19-patients-under-review-by-european-medicines-agency-ema
InflaRx's Marketing Authorization Applicat...
08/30/2023 11:32:05

hc-wainwright--co-reiterates-buy-on-inflarx-maintains-9-price-target
HC Wainwright & Co. Reiterates Buy on Infl...
08/11/2023 10:29:19

HC Wainwright & Co. analyst Edward White reiterates InflaRx (NASDAQ:IFRX) with a Buy and maintains $9 price target.

inflarx-q2-adj-eps-015-beats-034-estimate
InflaRx Q2 Adj EPS $(0.15) Beats $(0.34) E...
08/10/2023 13:00:56

InflaRx (NASDAQ:IFRX) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.34) by 55...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION